Opposing regulation of endoplasmic reticulum retention under stress by ERp44 and PDIA6
Biochemical Journal · 2024
DOI: 10.1042/bcj20240444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2024. Verfasst von Olaya Yassin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Protein Disulfide-Isomerases, Endoplasmic Reticulum, Endoplasmic Reticulum Stress, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Conditions of endoplasmic reticulum (ER) stress reduce protein synthesis by provoking translation regulation, governed by the eIF2α kinase PERK. When PERK is inhibited during ER stress, retention of a selective subset of glycoproteins occurs, a phenomenon we termed selective ER retention (sERr). sERr clients are enriched with tyrosine kinase receptors (RTKs), which form large molecular weight disulfide bonded complexes in the ER. The protein disulfide isomerase ERp44 promotes sERr and increases the size of sERr complexes. Here we show that sERr is reversible upon washout. Pulse chase analyses show that upon recovery, only a small fraction of the sERr complexes disintegrates and contributes to the matured proteins, while most are newly synthesized. Sequential inductions of sERr and washouts demonstrate an accelerated recovery that is dependent on the unfolded protein response transducer IRE1. Since IRE1 regulates the expression level PDIA6, we analyzed its contribution to sERr. We found that PDIA6 and ERp44 constitutively interact by disulfides and have opposite effects on resumed recovery of trafficking following removal of sERr conditions. Deletion of ERp44 accelerates, while deletion of PDIA6 slows down recovery with a minimal effect on total protein synthesis. ERp44 is a primary interactor with sERr clients. When missing, PDIA6 partitions more into sERr complexes. Deletion of the tumor suppressor PTEN, which induces RTK signaling, promoted sERr formation kinetics, and accelerated the recovery, suggesting feedback between RTKs signaling and sERr. This study suggests that sERr, should develop physiologically or pathologically, is counteracted by adaptation responses that involve IRE1 and PDIA6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH, U.S.A.
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, U.S.A.
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, U.S.A.
ORCID-Profile: Boaz Tirosh
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NIH HHS
- Israel Science Foundation
- HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases
- HHS | NIH | National Cancer Institute
Zitieren
APA
Yassin, O., Praveen, B., Darawshi, O., LaFramboise, T., Shmuel, M., Pattanayak, S. P., Law, B. K., Hatzoglou, M., & Tirosh, B. (2024). Opposing regulation of endoplasmic reticulum retention under stress by ERp44 and PDIA6. Biochemical Journal. https://doi.org/10.1042/bcj20240444
Vancouver
Yassin O, Praveen B, Darawshi O, LaFramboise T, Shmuel M, Pattanayak SP, et al. Opposing regulation of endoplasmic reticulum retention under stress by ERp44 and PDIA6. Biochemical Journal. 2024. doi:10.1042/bcj20240444
BibTeX
@article{Yassin2024,
author = {Yassin, Olaya and Praveen, Bellam and Darawshi, Odai and LaFramboise, Thomas and Shmuel, Miriam and Pattanayak, Shakti P and Law, Brian K and Hatzoglou, Maria and Tirosh, Boaz},
title = {Opposing regulation of endoplasmic reticulum retention under stress by ERp44 and PDIA6},
journal = {Biochemical Journal},
year = {2024},
doi = {10.1042/bcj20240444}
}
EUVIMED